Clinical and pharmacogenetic data confirm the safety and suitability of TLC-6740 for use in conjunction with GLP-1 receptor agonists and proton pump inhibitors across genomic profiles Preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback